Literature DB >> 10375397

Characterization of point mutations in patients with pyruvate dehydrogenase deficiency: role of methionine-181, proline-188, and arginine-349 in the alpha subunit.

A Tripatara1, L G Korotchkina, M S Patel.   

Abstract

Human pyruvate dehydrogenase (E1), a heterotetramer (alpha2beta2), is the first component of the pyruvate dehydrogenase complex (PDC). E1 catalyzes the thiamin pyrophosphate (TPP)-dependent decarboxylation of pyruvate and the reductive acetylation of the dihydrolipoamide acetyltransferase component. Site-directed mutagenesis was employed to recreate three point mutations in the alpha subunit identified in E1-deficient patients, M181V, R349H, and P188L (P188A mutant E1 was used because of the very low level of expression of P188L), to investigate the functional roles of these three amino acid residues. P188A mutant E1 was much less thermostable than the wild-type E1. The kcats of M181V and P188A mutant E1s determined in the PDC reaction were 38 and 24% of that of the wild-type enzyme, respectively. The apparent Km for TPP for M181V increased significantly (approx 250-fold when determined in the PDC assay), while the apparent Km for pyruvate increased by only about 3-fold. In contrast, P188A had similar Kms for the coenzyme and the substrate as the wild-type. Km values for R349H were not determined due to the extremely low activity of this mutant (1.2% of the wild-type E1-specific activity measured in the PDC assay). Wild-type E1 displayed a lag phase in the progress curve of the PDC reaction measured in the presence of low TPP concentrations (below 1 microM) only. All mutants had a lag phase that was not eliminated even at very high TPP concentrations, suggesting modifications in the conformation of the active site. Kinetic analysis indicated thiamin 2-thiothiazolone pyrophosphate (ThTTPP) to be an intermediate analog for wild-type human E1. M181V required a higher concentration of ThTTPP for inactivation than the wild-type and P188A E1s. The results of circular dichroism spectropolarimetry in the far UV region indicated that there were no major changes in the secondary structure of M181V, P188A, and R349H E1s. These mutant enzymes exhibited negative dichroic spectra at about 330 nm only in the presence of high TPP concentrations. This study suggests that arginine-349 is critical for E1's activity, methionine-181 is involved in the binding of TPP, and proline-188 is necessary for structural integrity of E1. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375397     DOI: 10.1006/abbi.1999.1231

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Folding and assembly defects of pyruvate dehydrogenase deficiency-related variants in the E1α subunit of the pyruvate dehydrogenase complex.

Authors:  Srdja Drakulic; Jay Rai; Steen Vang Petersen; Monika M Golas; Bjoern Sander
Journal:  Cell Mol Life Sci       Date:  2018-02-14       Impact factor: 9.261

2.  Thiamine-Responsive and Non-responsive Patients with PDHC-E1 Deficiency: A Retrospective Assessment.

Authors:  Sanne van Dongen; Ruth M Brown; Garry K Brown; David R Thorburn; Avihu Boneh
Journal:  JIMD Rep       Date:  2014-04-10

3.  Identification of Pyruvate Dehydrogenase E1 as a Potential Target against Magnaporthe oryzae through Experimental and Theoretical Investigation.

Authors:  Yuejuan Li; Baichun Hu; Zhibin Wang; Jianhua He; Yaoliang Zhang; Jian Wang; Lijie Guan
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

4.  Differential phenotypic expression of a novel PDHA1 mutation in a female monozygotic twin pair.

Authors:  Alejandro Horga; Catherine E Woodward; Alberto Mills; Isabel Pareés; Iain P Hargreaves; Ruth M Brown; Enrico Bugiardini; Tony Brooks; Andreea Manole; Elena Remzova; Shamima Rahman; Mary M Reilly; Henry Houlden; Mary G Sweeney; Garry K Brown; James M Polke; Federico Gago; Matthew J Parton; Robert D S Pitceathly; Michael G Hanna
Journal:  Hum Genet       Date:  2019-10-31       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.